Long-COVID neurological symptoms are associated with D-dimer levels in COVID-19 patients

myalgia Anosmia D-dimer
DOI: 10.18051/univmed.2022.v41.169-175 Publication Date: 2022-08-15T07:27:11Z
ABSTRACT
Background Coronavirus disease 2019 (COVID-19) is a designated as global pandemic by the WHO that can manifest clinically neurological disorders occur in acute phase or after (long COVID-19), such headache, myalgia, anosmia, and cognitive impairment. These symptoms of long COVID-19 are presumably caused hypercoagulable conditions characterized an increase D-dimer level. This study aims to determine correlation with role biomarker symptoms. MethodsThis was cross-sectional involving 31 patients Admitted cases recorded levels definitive outcomes were included consecutively. Long collected. level measured using immunofluorescence assay reported fibrinogen equivalent units (ìg/mL). The between clinical manifestations assessed ordinal regression analysis. p-value <0.05 considered statistically significant. ResultsThe mean age subjects 38.81 ± 11.58 years 18 (58.06%) female. COVID comprised anosmia cephalgia, most complained myalgia (80.65%). On multivariable analysis, long-COVID-19 significantly correlated [odds ratio (OR) = 1.05; p=0.020]. ConclusionThe number D-Dimer. Ultimately, more clarity needed on impact COVID-19, its diagnosis, treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)